KLOW peptide side effects
The KLOW peptide blend contains four compounds, each with its own safety profile. Because no clinical trials have studied the KLOW blend specifically, the side effect data comes from research on the individual compounds and from community reports. The overall tolerability appears favorable in short-term use, but there are meaningful concerns — particularly around BPC-157's angiogenic mechanism and the FDA's regulatory stance on two of the four compounds.
Common KLOW side effects
The most frequently reported side effects of KLOW in community protocols are mild and localized. Injection site redness or mild irritation is the most common, occurring in an estimated 10–15% of users and typically resolving within 30 minutes. Mild headache during the first few days of use is reported by some users, likely related to the vasodilatory effects of BPC-157 and TB-500. Transient fatigue or drowsiness — often reported as "feeling relaxed" — appears in the first week, particularly with evening dosing. Mild nausea is occasionally reported during the titration period and typically resolves within a few days.
These common side effects are consistent with the individual compound profiles and are generally not considered reasons to discontinue the protocol. The KLOW dosing guide includes a titration schedule specifically designed to minimize these effects by starting at a lower dose and increasing gradually.
BPC-157 side effects in the KLOW blend
BPC-157 is the most extensively studied compound in the KLOW blend, with hundreds of preclinical publications. Its primary safety concern is its angiogenic mechanism — BPC-157 promotes the formation of new blood vessels, which is the same process that tumors exploit to grow and metastasize. There is no direct evidence that BPC-157 causes or promotes cancer in animal models (and in some studies it has shown anti-tumor effects), but the theoretical concern remains unresolved because no long-term human studies exist.
Individuals with a current cancer diagnosis, a history of cancer within the past 5 years, or a strong family history of angiogenesis-dependent cancers should discuss this risk with an oncologist before using BPC-157 or any KLOW protocol. For the full BPC-157 safety profile, see the BPC-157 side effects guide.
GHK-Cu side effects in the KLOW blend
GHK-Cu is generally considered the safest compound in the KLOW blend. It's a naturally occurring peptide in human plasma, and supplemental doses are within the range of physiological variation. The primary consideration is copper accumulation — GHK-Cu delivers copper ions alongside the peptide, and excessive copper intake over extended periods could theoretically contribute to copper overload. However, the copper content per dose of GHK-Cu in the KLOW blend is well below the tolerable upper intake level for copper (10 mg/day), making clinical copper toxicity unlikely at standard doses.
Individuals with Wilson's disease (a genetic condition causing copper accumulation) should not use GHK-Cu or the KLOW blend. For healthy individuals, copper levels are not typically a concern at standard KLOW cycle lengths (4–8 weeks). Extended use beyond 12 weeks may warrant monitoring serum copper and ceruloplasmin levels. For the complete GHK-Cu safety profile, see the GHK-Cu research guide.
TB-500 side effects in the KLOW blend
TB-500 shares the angiogenesis concern with BPC-157 — it promotes blood vessel formation and cell migration, both of which are processes that tumors can exploit. The same precautionary guidance applies: individuals with active cancer or recent cancer history should avoid TB-500 and therefore the KLOW blend. In preclinical studies, TB-500 has not shown tumor-promoting effects, but the absence of evidence is not evidence of absence, particularly without long-term human data.
TB-500 may also affect blood clotting through its interaction with actin-binding proteins, though clinically significant bleeding events have not been reported. Individuals on anticoagulant therapy should discuss TB-500 use with their prescriber.
KPV side effects in the KLOW blend
KPV has the most favorable safety profile of the four KLOW compounds. As a tripeptide fragment of alpha-MSH — a naturally occurring neuropeptide — KPV operates within physiological signaling pathways. Unlike the full-length alpha-MSH molecule, KPV lacks melanotropic activity (it does not darken skin) and does not significantly affect appetite or energy balance.
No significant adverse effects have been reported for KPV in preclinical studies or community use. The primary theoretical concern is immunosuppression — KPV inhibits NF-κB, which is a central mediator of immune response. Excessive or prolonged NF-κB suppression could theoretically impair the body's ability to fight infections. However, KPV's effect on NF-κB is modulatory rather than absolute, and clinically relevant immunosuppression has not been observed at the doses used in KLOW protocols. For the full KPV safety profile, see the KPV research guide.
KLOW peptide FDA status
The KLOW blend's regulatory position is complicated by the mixed status of its components. Two of the four compounds — BPC-157 and TB-500 — are on the FDA's Category 2 list of bulk drug substances that may present significant safety risks in compounding. This means licensed 503A compounding pharmacies in the United States cannot legally prepare these compounds under Section 503A of the FD&C Act. GHK-Cu and KPV are not on the Category 2 list but are also not FDA-approved for therapeutic use.
Regulatory reality
KLOW is available through compounding pharmacies and research peptide suppliers, but its availability does not imply FDA approval or regulatory endorsement. The FDA has specifically stated that compounded drugs containing BPC-157 may pose safety risks. Users should understand that KLOW has not been reviewed by the FDA for safety, effectiveness, or quality, and that the purity and potency of compounded products can vary between suppliers.
Who should not use the KLOW peptide
Based on the combined safety profiles of the four compounds, KLOW should be avoided by individuals with active cancer or a cancer diagnosis within the past 5 years (due to the angiogenic effects of BPC-157 and TB-500), individuals with Wilson's disease or known copper metabolism disorders (due to GHK-Cu's copper content), individuals who are pregnant or breastfeeding (no safety data exists for any of the four compounds during pregnancy), individuals on anticoagulant therapy (without prescriber approval, due to TB-500's potential effects on coagulation), and individuals with active systemic infections (due to KPV's NF-κB-suppressing effects, which could theoretically impair immune response during acute infection).
Has anyone died from using KLOW?
No deaths have been attributed to the KLOW blend or any of its individual components in published literature or pharmacovigilance databases. However, the absence of reported deaths does not establish safety — the KLOW blend has not been studied in clinical trials, and adverse event reporting for compounded and research peptides is largely voluntary.
Can KLOW interact with medications?
Potential interactions have not been formally studied. The most likely interaction concerns are TB-500 with anticoagulants (potential additive bleeding risk) and KPV with immunosuppressive medications (potential additive immunosuppression). Patients on prescription medications should discuss KLOW with their prescriber before starting a protocol.
Is KLOW banned in sport?
BPC-157 and TB-500 are both classified as S0 (Non-Approved Substances) on the WADA Prohibited List and are banned in competitive sport. Any athlete subject to WADA testing should not use the KLOW blend. GHK-Cu and KPV are not specifically listed but may be flagged under the S0 category as unapproved substances.